Evoke Pharma received a notice of non-compliance with minimum stockholders' equity requirements from Nasdaq, where its equity of $2.1 million was less than the $2.5 million required. Evoke has submitted a plan for regaining compliance and Nasdaq has given them an extension until November 20, 2023 to comply. If the plan fails, the company may face delisting from Nasdaq.